Sign in
TerminatedPhase 1

Glutamine PET Imaging Colorectal Cancer

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
6 people enrolled
Started
27 Apr 2021
Ended
23 Dec 2025
Type of study
Interventional
Treatments tested
  • Carbon C 11 Glutamine
  • Fluorine F 18 L-glutamate Derivative BAY94-9392
  • Positron Emission Tomography
  • Blood Draw
Record updated
2 January 2026
Why it stopped
\<75% participation

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • ≥18 years of age
  • Pathologically or cytologically confirmed diagnosis of metastatic (Stage IV) RAS wildtype CRC
  • Eligible for anti-EGFR monoclonal antibody (mAb) therapy as standard-of-care (SOC), either as a single agent or in combination with approved SOC therapies or investigational agents as part of IRB-approved clinical trials
  • Archived tissue from the CRC primary tumor in sufficient amounts to allow RNA-seq gene analysis; specimen from metastatic sites are not required but highly preferred
  • Documented results from (or scheduled to undergo) CT or MRI of the chest, abdomen and pelvis as a standard-of-care procedure within 28 days of baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • At least one lesion >2 cm in diameter and thus will be measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0 to avoid PET partial volume effects
  • Ability to provide written informed consent in accordance with institutional policies

Who cannot take part

  • Any other current or previous malignancy within the past 5 years
  • Previous EGFR-directed therapy
  • Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
  • Pregnant or lactating females

Where in United States

  • M D Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.

The group in the trial

  • TreatmentTreatment being tested

    Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.

    Treatment: Carbon C 11 Glutamine, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography, and Blood Draw

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Glutamine PET Imaging of Colorectal Cancer
Record updated
2 January 2026